GPR63 (gpr63_human)
FAMILY
Class A (Rhodopsin) Orphan receptors Class A orphans GPR63
GENE
GPR63 (PSP24B)
ORGANISM
Human (Homo sapiens)
ALT. NAMES
Probable G-protein coupled receptor 63, PSP24-2, PSP24-beta
SOURCE
SWISSPROT
SEQUENCE
N-term | |||||||||
M
|
V
|
F
|
S
|
A
|
V
|
L
|
T
|
A
|
F
|
10 |
H
|
T
|
G
|
T
|
S
|
N
|
T
|
T
|
F
|
V
|
20 |
V
|
Y
|
E
|
N
|
T
|
Y
|
M
|
N
|
I
|
T
|
30 |
L
|
P
|
P
|
P
|
F
|
Q
|
H
|
P
|
D
|
L
|
40 |
S
|
P
|
L
|
L
|
R
|
Y
|
S
|
F
|
E
|
T
|
50 |
M
|
A
|
P
|
T
|
G
|
L
|
S
|
S
|
L
|
T
|
60 |
V
|
N
|
S
|
T
|
A
|
V
|
P
|
T
|
T
|
P
|
70 |
TM1 | |||||||||
A
|
A
|
F
|
K
|
S
|
L
|
N
|
L
|
P
|
L
|
80 |
Q
|
I
|
T
|
L
|
S
|
A
|
I
|
M
|
I
|
F
|
90 |
I
|
L
|
F
|
V
|
S
|
F
|
L
|
G
|
N
|
L
|
100 |
V
|
V
|
C
|
L
|
M
|
V
|
Y
|
Q
|
K
|
A
|
110 |
ICL1 | TM2 | ||||||||
A
|
M
|
R
|
S
|
A
|
I
|
N
|
I
|
L
|
L
|
120 |
A
|
S
|
L
|
A
|
F
|
A
|
D
|
M
|
L
|
L
|
130 |
A
|
V
|
L
|
N
|
M
|
P
|
F
|
A
|
L
|
V
|
140 |
ECL1 | |||||||||
T
|
I
|
L
|
T
|
T
|
R
|
W
|
I
|
F
|
G
|
150 |
TM3 | |||||||||
K
|
F
|
F
|
C
|
R
|
V
|
S
|
A
|
M
|
F
|
160 |
F
|
W
|
L
|
F
|
V
|
I
|
E
|
G
|
V
|
A
|
170 |
I
|
L
|
L
|
I
|
I
|
S
|
I
|
D
|
R
|
F
|
180 |
ICL2 | |||||||||
L
|
I
|
I
|
V
|
Q
|
R
|
Q
|
D
|
K
|
L
|
190 |
TM4 | |||||||||
N
|
P
|
Y
|
R
|
A
|
K
|
V
|
L
|
I
|
A
|
200 |
V
|
S
|
W
|
A
|
T
|
S
|
F
|
C
|
V
|
A
|
210 |
ECL2 | |||||||||
F
|
P
|
L
|
A
|
V
|
G
|
N
|
P
|
D
|
L
|
220 |
Q
|
I
|
P
|
S
|
R
|
A
|
P
|
Q
|
C
|
V
|
230 |
F
|
G
|
Y
|
T
|
T
|
N
|
P
|
G
|
Y
|
Q
|
240 |
TM5 | |||||||||
A
|
Y
|
V
|
I
|
L
|
I
|
S
|
L
|
I
|
S
|
250 |
F
|
F
|
I
|
P
|
F
|
L
|
V
|
I
|
L
|
Y
|
260 |
S
|
F
|
M
|
G
|
I
|
L
|
N
|
T
|
L
|
R
|
270 |
H
|
N
|
A
|
L
|
R
|
I
|
H
|
S
|
Y
|
P
|
280 |
ICL3 | |||||||||
E
|
G
|
I
|
C
|
L
|
S
|
Q
|
A
|
S
|
K
|
290 |
L
|
G
|
L
|
M
|
S
|
L
|
Q
|
R
|
P
|
F
|
300 |
TM6 | |||||||||
Q
|
M
|
S
|
I
|
D
|
M
|
G
|
F
|
K
|
T
|
310 |
R
|
A
|
F
|
T
|
T
|
I
|
L
|
I
|
L
|
F
|
320 |
A
|
V
|
F
|
I
|
V
|
C
|
W
|
A
|
P
|
F
|
330 |
T
|
T
|
Y
|
S
|
L
|
V
|
A
|
T
|
F
|
S
|
340 |
ECL3 | |||||||||
K
|
H
|
F
|
Y
|
Y
|
Q
|
H
|
N
|
F
|
F
|
350 |
TM7 | |||||||||
E
|
I
|
S
|
T
|
W
|
L
|
L
|
W
|
L
|
C
|
360 |
Y
|
L
|
K
|
S
|
A
|
L
|
N
|
P
|
L
|
I
|
370 |
H8 | |||||||||
Y
|
Y
|
W
|
R
|
I
|
K
|
K
|
F
|
H
|
D
|
380 |
A
|
C
|
L
|
D
|
M
|
M
|
P
|
K
|
S
|
F
|
390 |
C-term | |||||||||
K
|
F
|
L
|
P
|
Q
|
L
|
P
|
G
|
H
|
T
|
400 |
K
|
R
|
R
|
I
|
R
|
P
|
S
|
A
|
V
|
Y
|
410 |
V
|
C
|
G
|
E
|
H
|
R
|
T
|
V
|
V
|
LINKS
DIAGRAMS
Pick color:
Invitro Mutant Data: Increased binding/potency: >5-fold, >10-fold; Reduced binding/potency: >5-fold, >10-fold; No/low effect (<5-fold); and N/A
Pick color:
Invitro Mutant Data: Increased binding/potency: >5-fold, >10-fold; Reduced binding/potency: >5-fold, >10-fold; No/low effect (<5-fold); and N/A
MUTATIONS
PHYSIOLOGICAL LIGANDS
[(2S)-2-[(Z)-octadec-9-enoyl]oxy-3-phosphonooxypropyl] (Z)-octadec-9-enoate, dihydrosphingosine 1-phosphate, dioleoylphosphatidic acid, 1,2-Dioleoyl-sn-glycerol-3-phosphate, sphingosine 1-phosphate
STRUCTURE MODELS
STRUCTURES
No structures available